Xilio Therapeutics, Inc. ( XLO) Stock. Should you Buy or Sell? $ 2.75
0.51 (15.64 %)
Xilio Therapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | XLO |
| Price | $2.75 |
| Beta | 0.000 |
| Volume Avg. | $115.34 thousand |
| Market Cap | $75.55 M |
| 52 Week Range | $2.01 - $27.95 |
Xilio Therapeutics, Inc. opened the day at $2.75 which is +'15.64 % on yesterday's close. Xilio Therapeutics, Inc. has a 52 week high of $27.95 and 52 week low of $2.01, which is a difference of $25.94. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $75.55 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Xilio Therapeutics, Inc. for $75.55 M, it would take 15 years to get your money back. Xilio Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Xilio Therapeutics, Inc. Stock Forecast - Is Xilio Therapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.919 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Xilio Therapeutics, Inc.
| Price Book Value Ratio | 0.522 | Price To Book Ratio | 0.522 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.919 |
How liquid is Xilio Therapeutics, Inc.
| Current Ratio | 9.173 |
| Quick Ratio | 8.971 |
Debt
| Debt Ratio | 0.190 | Debt Equity Ratio | 0.235 |
| Long Term Debt To Capitalization | 0.100 | Total Debt To Capitalization | 0.123 |
Latest news about Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate virtually in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 2:55 p.m. ET.
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 2:30 p.m. ET.
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 8:00 a.m. ET.
Xilio Therapeutics has filed proposed terms for a $125 million IPO. The firm is developing immuno-oncology-based treatments for solid tumors and other cancer conditions.
About Xilio Therapeutics, Inc.
Description :
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
